keyword
MENU ▼
Read by QxMD icon Read
search

Chemotherapeutic agent induced cardiomyopathy

keyword
https://www.readbyqxmd.com/read/29867456/a-review-on-the-effect-of-traditional-chinese-medicine-against-anthracycline-induced-cardiac-toxicity
#1
REVIEW
Xinyu Yang, Nian Liu, Xinye Li, Yihan Yang, Xiaofeng Wang, Linling Li, Le Jiang, Yonghong Gao, Hebin Tang, Yong Tang, Yanwei Xing, Hongcai Shang
Anthracyclines are effective agents generally used to treat solid-tumor and hematologic malignancies. The use of anthracyclines for over 40 years has improved cancer survival statistics. Nevertheless, the clinical utility of anthracyclines is limited by its dose-dependent cardiotoxicity that adversely affects 10-30% of patients. Anthracycline-induced cardiotoxicity may be classified as acute/subacute or chronic/late toxicity and leads to devastating adverse effects resulting in poor quality of life, morbidity, and premature mortality...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29806528/recovery-from-anthracycline-induced-cardiomyopathy-with-biventricular-assist-and-valve-repairs-a-case-report-and-literature-review
#2
Yoshiyuki Takami, Naoki Hoshino, Yasuchika Kato, Yusuke Sakurai, Kentaro Amano, Yoshiro Higuchi, Masato Tochii, Michiko Ishida, Hiroshi Ishikawa, Yasushi Takagi, Yukio Ozaki
INTRODUCTION: Ventricular assist device is used in the patients with severe heart failure due to cardiotoxicity of anthracyclines, which are widely used chemotherapeutic agents for a wide range of malignant tumors. However, recovery of cardiac function is rare. METHODS: We present the clinical course of a 43-year-old woman in remission from diffuse large B-cell lymphoma after the chemotherapy including anthracyclines, who presented in cardiogenic shock 8 months after the end of chemotherapy...
May 1, 2018: International Journal of Artificial Organs
https://www.readbyqxmd.com/read/29552206/protective-effect-of-berberine-on-acute-cardiomyopathy-associated-with-doxorubicin-treatment
#3
Chen Xiong, Yan-Zhao Wu, Yu Zhang, Zi-Xiao Wu, Xue-Yan Chen, Ping Jiang, Hui-Cai Guo, Ke-Rang Xie, Ke-Xin Wang, Su-Wen Su
Doxorubicin (DOX) is a potent and broad-spectrum anthracycline chemotherapeutic agent, but dose-dependent cardiotoxic side effects limit its clinical application. This toxicity is closely associated with the generation of reactive oxygen species (ROS) radical during DOX metabolism. The present study investigated the effects of Berberine (Ber) on DOX-induced acute cardiac injury in a rat model and analysed its mechanism in cardiomyocytes in vitro . Serum creatine kinase (CK), creatine kinase isoenzyme (CK-MB) and malondialdehyde (MDA) levels were significantly increased in the DOX group compared with the control group...
April 2018: Oncology Letters
https://www.readbyqxmd.com/read/29458045/aldose-reductase-inhibitor-fidarestat-prevents-doxorubicin-induced-endothelial-cell-death-and-dysfunction
#4
Himangshu Sonowal, Pabitra Pal, Kirtikar Shukla, Ashish Saxena, Satish K Srivastava, Kota V Ramana
Despite doxorubicin (Dox) being one of the most widely used chemotherapy agents for breast, blood and lung cancers, its use in colon cancer is limited due to increased drug resistance and severe cardiotoxic side effects that increase mortality associated with its use at high doses. Therefore, better adjuvant therapies are warranted to improve the chemotherapeutic efficacy and to decrease cardiotoxicity. We have recently shown that aldose reductase inhibitor, fidarestat, increases the Dox-induced colon cancer cell death and reduces cardiomyopathy...
April 2018: Biochemical Pharmacology
https://www.readbyqxmd.com/read/29385562/expression-profiling-of-human-pluripotent-stem-cell-derived-cardiomyocytes-exposed-to-doxorubicin-integration-and-visualization-of-multi-omics-data
#5
Gustav Holmgren, Peter Sartipy, Christian X Andersson, Anders Lindahl, Jane Synnergren
Anthracyclines, such as doxorubicin, are highly efficient chemotherapeutic agents against a variety of cancers. However, anthracyclines are also among the most cardiotoxic therapeutic drugs presently on the market. Chemotherapeutic-induced cardiomyopathy is one of the leading causes of disease and mortality in cancer survivors. The exact mechanisms responsible for doxorubicin-induced cardiomyopathy are not completely known, but the fact that the cardiotoxicity is dose-dependent and that there is a variation in time-to-onset of toxicity, and gender- and age differences suggests that several mechanisms may be involved...
January 27, 2018: Toxicological Sciences: An Official Journal of the Society of Toxicology
https://www.readbyqxmd.com/read/29377985/cancer-therapy-induced-cardiomyopathy-can-human-induced-pluripotent-stem-cell-modelling-help-prevent-it
#6
Jonathan P Stack, Javid Moslehi, Nazish Sayed, Joseph C Wu
Cardiotoxic effects from cancer therapy are a major cause of morbidity during cancer treatment. Unexpected toxicity can occur during treatment and/or after completion of therapy, into the time of cancer survivorship. While older drugs such as anthracyclines have well-known cardiotoxic effects, newer drugs such as tyrosine kinase inhibitors, proteasome inhibitors, and immunotherapies also can cause diverse cardiovascular and metabolic complications. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are increasingly being used as instruments for disease modelling, drug discovery, and mechanistic toxicity studies...
January 25, 2018: European Heart Journal
https://www.readbyqxmd.com/read/28920632/acute-cardiotoxicity-induced-by-doxorubicin-in-right-ventricle-is-associated-with-increase-of-oxidative-stress-and-apoptosis-in-rats
#7
N Anghel, H Herman, C Balta, M Rosu, M S Stan, D Nita, A Ivan, Z Galajda, A Ardelean, A Dinischiotu, A Hermenean
Doxorubicin (DOX) is one of the most effective chemotherapeutic agents, but its efficiency is seriously limited by the risk of developing cardiomyopathy. The most recognized cardiotoxic effect is left ventricular (LF) dysfunction, but MRI and echocardiography data demonstrated significant right ventricle (RV) function impairment. In order to clarify this aspect, the present study investigated the potential of DOX to induce acute RV cardiotoxicity at the same time as LV impairment. Rats were intraperitoneally (i...
April 2018: Histology and Histopathology
https://www.readbyqxmd.com/read/28684738/mechanistic-clues-to-the-protective-effect-of-chrysin-against-doxorubicin-induced-cardiomyopathy-plausible-roles-of-p53-mapk-and-akt-pathways
#8
Eman M Mantawy, Ahmed Esmat, Wesam M El-Bakly, Rania A Salah ElDin, Ebtehal El-Demerdash
Doxorubicin (DOX) is the mainstay chemotherapeutic agent against a variety of human neoplasmas. However, its clinical utility is limited by its marked cardiotoxicity. Chrysin, is a natural flavone which possesses antioxidant, anti-inflammatory and anti-cancer properties. The current study aimed to investigate the potential protective effect of chrysin against DOX-induced chronic cardiotoxicity and the underlying molecular mechanisms. Male Sprague-Dawley rats were treated with either DOX (5 mg/kg, once a week) and/or chrysin (50 mg/kg, four times a week) for four weeks...
July 6, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28662206/early-transcriptional-alteration-of-histone-deacetylases-in-a-murine-model-of-doxorubicin-induced-cardiomyopathy
#9
Izabela Piotrowska, Mark Isalan, Michal Mielcarek
Doxorubicin is a potent chemotherapeutic agent that is widely-used to treat a variety of cancers but causes acute and chronic cardiac injury, severely limiting its use. Clinically, the acute side effects of doxorubicin are mostly manageable, whereas the delayed consequences can lead to life-threatening heart failure, even decades after cancer treatment. The cardiotoxicity of doxorubicin is subject to a critical cumulative dose and so dosage limitation is considered to be the best way to reduce these effects...
2017: PloS One
https://www.readbyqxmd.com/read/28474324/role-of-imaging-in-cardio-oncology
#10
REVIEW
Erick Avelar, Caitlin R Strickland, Guido Rosito
Recent advances in cancer treatment and research have greatly improved survival rates for patients with cancer. However, many of these cancer survivors are developing cardiac disease-most commonly heart failure as a result of this treatment. Certain chemotherapeutic agents, including anthracyclines and trastuzumab, have been linked to cardiotoxicity-induced cardiomyopathy in cancer patients. It has been reported as early as during infusion and as late as several years following treatment. Radiation therapy, particularly to the left breast, has also been linked to cardiac disease...
June 2017: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28428026/dietary-cyanidin-3-glucoside-from-purple-corn-ameliorates-doxorubicin-induced-cardiotoxicity-in-mice
#11
K Petroni, M Trinei, M Fornari, V Calvenzani, A Marinelli, L A Micheli, R Pilu, A Matros, H-P Mock, C Tonelli, M Giorgio
BACKGROUND AND AIMS: Anthracyclines are effective anticancer drugs that have improved prognosis of hundred thousand cancer patients worldwide and are currently the most common chemotherapeutic agents used for the treatment of blood, breast, ovarian and lung cancers. However, their use is limited because of a cumulative dose-dependent and irreversible cardiotoxicity that can cause progressive cardiomyopathy and congestive heart failure. Aim of the present study was to determine the cardioprotective activity of a dietary source of cyanidin 3-glucoside (C3G), such as purple corn, against doxorubicin (DOX)-induced cardiotoxicity in mice...
May 2017: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/28367338/folfox-induced-takotsubo-cardiomyopathy-treated-with-impella-assist-device
#12
Swethika Sundaravel, Abdulah Alrifai, Mohamad Kabach, Waqas Ghumman
Chemotherapy induced cardiotoxicity is becoming increasingly prevalent with several new agents being used recently. The incidence of Takotsubo cardiomyopathy due to 5-fluorouracil based chemotherapeutic regimens like FOLFOX is not uncommon. It is also seen with platinum based chemotherapy. Most of these patients have reversible cardiotoxicity and the cardiac function recovers within a short period with supportive treatment. Here we have a patient who presented with cardiogenic shock after 5 days of receiving FOLFOX regimen for colorectal adenocarcinoma...
2017: Case Reports in Cardiology
https://www.readbyqxmd.com/read/28295305/mitochondrial-ros-induced-erk1-2-activation-and-hsf2-mediated-at1-r-upregulation-are-required-for-doxorubicin-induced-cardiotoxicity
#13
Chih-Yang Huang, Jia-Yi Chen, Chia-Hua Kuo, Pei-Ying Pai, Tsung-Jung Ho, Tung-Sheng Chen, Fu-Jen Tsai, Vijaya V Padma, Wei-Wen Kuo, Chih-Yang Huang
Doxorubicin (DOX), one useful chemotherapeutic agent, is limited in clinical use because of its serious cardiotoxicity. Growing evidence suggests that angiotensin receptor blockers (ARBs) have cardioprotective effects in DOX-induced cardiomyopathy. However, the detailed mechanisms underlying the action of ARBs on the prevention of DOX-induced cardiomyocyte cell death have yet to be investigated. Our results showed that angiotensin II receptor type I (AT1 R) plays a critical role in DOX-induced cardiomyocyte apoptosis...
January 2018: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/27965861/exercise-to-prevent-anthrcycline-based-cardio-toxicity-exact-in-individuals-with-breast-or-hematological-cancers-a-feasibility-study-protocol
#14
Melanie R Keats, Scott A Grandy, Nicholas Giacomantonio, David MacDonald, Miroslaw Rajda, Tallal Younis
BACKGROUND: Anthracyclines (AC), widely used and effective anticancer agents, are known to induce both acute and chronic declines in cardiovascular health, ranging in severity from asymptomatic, subclinical dysfunction to substantial cardiomyopathy leading to congestive heart failure and death. There is substantial evidence that physical activity, higher levels of cardiorespiratory fitness, and exercise therapy can help prevent cardiovascular disease. Moreover, animal studies have shown that exercise performed concomitantly with AC treatment may attenuate early cardiac damage that results from AC exposure...
2016: Pilot and Feasibility Studies
https://www.readbyqxmd.com/read/27933370/doxorubicin-induced-chronic-dilated-cardiomyopathy-the-apoptosis-hypothesis-revisited
#15
REVIEW
Cynthia Kankeu, Kylie Clarke, Egle Passante, Heinrich J Huber
The chemotherapeutic agent doxorubicin (DOX) has significantly increased survival rates of pediatric and adult cancer patients. However, 10% of pediatric cancer survivors will 10-20 years later develop severe dilated cardiomyopathy (DCM), whereby the exact molecular mechanisms of disease progression after this long latency time remain puzzling. We here revisit the hypothesis that elevated apoptosis signaling or its increased likelihood after DOX exposure can lead to an impairment of cardiac function and cause a cardiac dilation...
March 2017: Journal of Molecular Medicine: Official Organ of the "Gesellschaft Deutscher Naturforscher und Ärzte"
https://www.readbyqxmd.com/read/27926539/chemotherapy-related-cardiac-dysfunction-grey-area-in-type-i-and-type-ii-classification
#16
Rohit Moudgil, Haissam Haddad
PURPOSE OF REVIEW: The main aim of this review is to address and challenge an old nomenclature of reversible versus irreversible chemotherapy-induced cardiomyopathy. RECENT FINDINGS: Chemotherapy-related cardiac dysfunction (CRCD) has been often characterized as type I or type II. Type I CRCD (e.g., anthracycline) represents a group of chemotherapeutic agents that has often been correlated with irreversible cardiac dysfunction. Conversely, type II CRCD (e.g., trastuzumab) represents a group of anticancer agents that has been considered as reversible...
March 2017: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/27755245/novel-insights-in-pathophysiology-of-antiblastic-drugs-induced-cardiotoxicity-and-cardioprotection
#17
REVIEW
Martino Deidda, Rosalinda Madonna, Ruggiero Mango, Pasquale Pagliaro, Pier P Bassareo, Lucia Cugusi, Silvio Romano, Maria Penco, Francesco Romeo, Giuseppe Mercuro
Despite advances in supportive and protective therapy for myocardial function, heart failure caused by various clinical conditions, including cardiomyopathy due to antineoplastic therapy, remains a major cause of morbidity and mortality. Because of the limitations associated with current therapies, investigators have been searching for alternative treatments that can effectively repair the damaged heart and permanently restore its function. Damage to the heart can result from both traditional chemotherapeutic agents, such as anthracyclines, and new targeted therapies, such as trastuzumab...
May 2016: Journal of Cardiovascular Medicine
https://www.readbyqxmd.com/read/27609196/validating-the-pharmacogenomics-of-chemotherapy-induced-cardiotoxicity-what-is-missing
#18
REVIEW
Tarek Magdy, Brian T Burmeister, Paul W Burridge
The cardiotoxicity of certain chemotherapeutic agents is now well-established, and has led to the development of the field of cardio-oncology, increased cardiac screening of cancer patients, and limitation of patients' maximum cumulative chemotherapeutic dose. The effect of chemotherapeutic regimes on the heart largely involves cardiomyocyte death, leading to cardiomyopathy and heart failure, or the induction of arrhythmias. Of these cardiotoxic drugs, those resulting in clinical cardiotoxicity can range from 8 to 26% for doxorubicin, 7-28% for trastuzumab, or 5-30% for paclitaxel...
December 2016: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27461436/echocardiography-and-alternative-cardiac-imaging-strategies-for-long-term-cardiotoxicity-surveillance-of-cancer-survivors-treated-with-chemotherapy-and-or-radiation-exposure
#19
REVIEW
Vinisha Garg, Gabriel Vorobiof
Cardiotoxicity from chemotherapy is a leading cause of morbidity and mortality in cancer survivors. Cardiotoxic effects include left ventricular systolic dysfunction, coronary artery disease, hypertension, bradycardia, arrhythmias, pericardial disease, valvular disease, and radiation-induced restrictive cardiomyopathy. Noninvasive cardiac imaging has been at the forefront of detecting cardiotoxicity in patients receiving chemotherapeutic agents known to adversely affect cardiac structure and function. Regimens for cardiotoxicity surveillance prior to and during chemotherapy administration have been proposed; however, optimal screening for and treatment of long-term cancer survivors have yet to be clarified...
August 2016: Current Oncology Reports
https://www.readbyqxmd.com/read/27294099/sarco-mir-friend-or-foe-a-perspective-on-the-mechanisms-of-doxorubicin-induced-cardiomyopathy
#20
Louis A Saddic, Jochen D Muehlschlegel
Anthracyclines are a class of chemotherapeutics used to treat a variety of human cancers including both solid tumors such as breast, ovarian, and lung, as well as malignancies of the blood including leukemia and lymphoma. Despite being extremely effective anti-cancer agents, the application of these drugs is offset by side effects, most notably cardiotoxicity. Many patients treated with doxorubicin (DOX), one of the most common anthracyclines used in oncology, will develop radiographic signs and/or symptoms of cardiomyopathy...
May 2016: Annals of Translational Medicine
keyword
keyword
82652
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"